MK0359
Phase 2Small molecule
Merck & Co.MK0359 is one of 65 small molecule programs targeting Arthritis. It is currently in Phase 2.
3
Indications
3
Total Trials
0
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
557 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Veramyst
GSKPreclinical
Flovent
GSKPreclinical
Spiriva
Boehringer IngelheimPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
MK0359
Merck & Co.Phase 2
Duragesic
CCephalon
Preclinical
Narcan
SScienture
Preclinical
Coumadin
AAbbott
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Insulin Therapy
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MK0359. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company